US2023295340A1PendingUtilityA1

Muc1* antibodies

72
Assignee: MINERVA BIOTECHNOLOGIES CORPPriority: Oct 6, 2008Filed: Dec 6, 2022Published: Sep 21, 2023
Est. expiryOct 6, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:Cynthia BamdadSanjeev Mahanta
A61K 39/001117C07K 16/3092C07K 16/30A61K 2039/505C07K 2317/55C07K 2317/622C07K 2317/73A61P 35/00C12N 15/11C12N 5/16C07K 19/00C07K 2317/21C07K 2317/24C07K 2317/31C07K 2317/35C07K 2317/56C07K 2317/565C07K 2317/567C12N 5/0693C12N 2501/998
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present describes monoclonal antibodies.

Claims

exact text as granted — not AI-modified
1 - 50 . (canceled) 
     
     
         51 . An isolated monoclonal antibody that binds to Mucin-1 * (MUC1*), comprising:
 (a) a heavy chain (HC) variable region comprising a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 172, a HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 198, a HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 224, a HC-framework region 1 (FWR1) comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 362, a HC-FWR2 comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 363, and a HC-FWR3 comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 364; and   (b) a light chain (LC) variable region comprising a LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 108, a LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 129, a LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 149, a LC-FWR1 comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 365, a LC-FWR2 comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 366, and a LC-FWR3 comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 367.   
     
     
         52 . The antibody of  claim 51 , wherein:
 the HC-FWR1 comprises the amino acid sequence of SEQ ID NO: 362, the HC-FWR2 comprises the amino acid sequence of SEQ ID NO: 363, and the HC-FWR3 comprises the amino acid sequence of SEQ ID NO: 364; and   the LC-FWR1 comprises the amino acid sequence of SEQ ID NO: 365, the LC-FWR2 comprises the amino acid sequence of SEQ ID NO: 366, and the LC-FWR3 comprises the amino acid sequence of SEQ ID NO: 367.   
     
     
         53 . The antibody of  claim 51 , wherein the heavy chain variable region comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 11 and the light chain variable region comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 13. 
     
     
         54 . The antibody of  claim 51 , wherein the heavy chain variable region comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 11 and the light chain variable region comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 13. 
     
     
         55 . The antibody of  claim 51 , wherein the heavy chain variable region comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 11 and the light chain variable region comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 13. 
     
     
         56 . The antibody of  claim 51 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 11 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 13. 
     
     
         57 . The antibody of  claim 51 , wherein the antibody is monovalent for MUC1* and specifically binds to the MUC1* amino acid sequence of SEQ ID NO: 1. 
     
     
         58 . The antibody of  claim 57 , wherein the antibody inhibits MUC1*-mediated cell growth or proliferation. 
     
     
         59 . The antibody of  claim 51 , wherein the antibody binds specifically to a cancer cell. 
     
     
         60 . The antibody of  claim 51 , wherein the antibody is a Fab, F(ab′), F(ab′) 2 , or a single chain variable fragment antibody (scFv). 
     
     
         61 . The antibody of  claim 60 , wherein the Fab comprises a heavy chain comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 47 and/or a kappa chain comprising an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 48. 
     
     
         62 . The antibody of  claim 60 , wherein the Fab comprises a heavy chain comprising an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 47 and/or a kappa chain comprising an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 48. 
     
     
         63 . The antibody of  claim 60 , wherein the Fab comprises a heavy chain comprising an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 47 and/or a kappa chain comprising an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 48. 
     
     
         64 . The antibody of  claim 60 , wherein the Fab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 47 and/or a kappa chain comprising the amino acid sequence of SEQ ID NO: 48. 
     
     
         65 . The antibody of  claim 60 , wherein the scFv comprises an amino acid sequence with at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 17. 
     
     
         66 . The antibody of  claim 60 , wherein the scFv comprises an amino acid sequence with at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17. 
     
     
         67 . The antibody of  claim 60 , wherein the scFv comprises an amino acid sequence with at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 17. 
     
     
         68 . The antibody of  claim 60 , wherein the scFv comprises the amino acid sequence of SEQ ID NO: 17. 
     
     
         69 . The antibody of  claim 51 , wherein the antibody is bivalent for MUC1*. 
     
     
         70 . The antibody of  claim 51 , wherein the antibody is bispecific or trispecific. 
     
     
         71 . The antibody of  claim 70 , wherein a first portion of the antibody binds to MUC1* and a second portion binds to an immune cell or a tumor-specific antigen on a cell surface. 
     
     
         72 . The antibody of  claim 51 , wherein the antibody is fused to a label, a tag, a toxin, a radioactive substance, a targeting motif, a leader sequence peptide, a toxic material, a protein, or a peptide. 
     
     
         73 . The antibody of  claim 72 , wherein the protein is a toxin, or a cytokine.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.